Authors'reply

摘要

We thank Juan J Zarranz and Juan Carlos Gomez-Esteban for their comments. We agree that our data underestimated the prevalence of Gly2019Ser in the Basque country. As they have shown, carriers of the Gly2019Ser mutation in these regions share the common North African or Jewish LRRK2 haplotype, indicating that it is likely that the mutation entered the Basque country through population migrations. In this respect, the presence of the Gly2019Ser mutation in the Basque country does not differ from the rest of Spain,or Europe, unlike the Argl441Gly mutation, where the founder event probably occurred within the Basque population.Zarranz and Gomez Esteban also point out that their results for efficacy of bilateral deep brain subthalamic stimulation in four carriers of the Argl441Gly mutation were inferior to those reported by the International LRRK2 Consortium. We reported data from 12 patients with the Gly2019Ser mutation who had measured clinical outcomes from different institutions.